Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 7, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for August 6, 2008 Subscribe to this News Feed      
 

XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies

XTELL has launched a commercial biorepository service, bioVAULT, which stores, manages and processes large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development.

Athens, OH (PRWEB) August 6, 2008 -- XTELL announced today the launch of its commercialized, independent biorepository service stemming from its collaborations with The Ohio University Endocrine Diseases Biorepository. XTELL's "bioVAULT" service will provide storage of biological samples derived from human/animal serum and tissues with 100% guaranteed confidentiality. BioVAULT will allow clinicians and researchers alike to facilitate and link patient/family medical history.

News Image

Biorepositories are now critical in understanding the molecular mechanisms of disease and for the development of new therapeutics,
XTELL is a biotechnology company founded in 2001, dedicated to both the development of biological specimen storage and electronic medical record software.

A large part of XTELL's success has been from a direct partnership with Ohio University's Diabetes Center in creating a biorepository designed specifically for fundamental and translational research. Samples include DNA, RNA, and protein extracted from blood serum in patients living in a region of the United States with a high prevalence of diabetes and endocrine-related disease. XTELL has developed one of the most advanced diabetes biorepositories of its kind, with a state-of-the-art collection and storage facility.

BioVAULT is now capable of storing, managing and processing large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development, as well as universities. "Biorepositories are now critical in understanding the molecular mechanisms of disease and for the development of new therapeutics, " said Anthony Schwartz, President of XTELL.


XTELL is privately held and located in Athens, Ohio and is seeking new investors for building up its infrastructure as well as to secure its long-term growth.

Additional information is available at: http://www.xtell.com

Contact:
XTELL
Anthony Schwartz
President
Telephone: 1.800.314.0735
E-mail: info @ xtellnetworks.com

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1FbXB0LVN1bW0tQ3Jhcy1TaW5nLVNpbmctWmVybw==

OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Anthony Schwartz
XTELL
1-800-314-0735
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright